The DCVA-WCN Pitch is an event where cardiovascular researchers are given a platform to present groundbreaking ideas for clinical trials. Organized by the Werkgroep Cardiologie Nederland (WCN) in collaboration with the Dutch CardioVascular Alliance (DCVA) and the Withering Foundation Netherlands (WSN), this pitch event aims to identify and support high-impact, feasible research projects that can transform cardiovascular care. Previous winning projects include LoDoCo2, DUTCH-WAIST, and VeraPAF, each of which has made significant contributions to the
field. This pitch is designed to provide researchers, particularly WCN members and peripheral investigators, with a chance to showcase innovative ideas for clinical cardiovascular research. Submissions will be evaluated by a diverse panel based on criteria such as potential impact, feasibility, and alignment with the overarching mission of the DCVA. Collaboration between DCVA partners is highly encouraged, as teamwork is key to achieving lasting results.
The submission deadline has passed, and we are excited about the number and diversity of applications we received. The topics represent a wide range of innovative ideas and approaches, reflecting the creativity and ambition of the research community.
In January, the jury will review all submissions and select the most promising proposals for the next stage. The selected candidates will be invited to present their ideas during the pitch night on February 13, 2025. This event will be an excellent opportunity to showcase groundbreaking research and facilitate connections between researchers, partners, and stakeholders.
We warmly invite DCVA partners and the WCN network to join us for this inspiring evening. It will be a great occasion to explore new ideas, support innovative research, and connect with others in the field. To attend, please register by emailing info@dcvalliance.nl.
The aim of the LoDoCo2 (Low Dose Colchicine for secondary prevention of cardiovascular disease) trial was to investigate the effect of low dose colchicine (0,5 mg once daily) on the risk of myocardial infarction (fatal or non-fatal), stroke, or the need for coronary bypass or stent placement. While the precise mechanism through which colchicine mitigates major cardiovascular events remains incompletely understood, it is hypothesized that its anti-inflammatory effects contribute to risk reduction among patients with established atherosclerotic disease.
LoDoCo2 stands out in several respects. It represents a large-scale randomized clinical trial conducted entirely by a non-academic network of cardiologists and a consortium of pharmaceutical companies with a focus on drug repurposing. This trial underscores the potential value of older, often cost-effective medications in advancing the development of new innovative drugs.
Learn more
The DUTCH-WAIST study aims to address a common yet often overlooked cause of atrial fibrillation (AF): obesity. This study builds on the standard Combined Lifestyle Intervention by incorporating semaglutide injections, which promote significant weight loss. The weight reduction not only helps to manage obesity but also positively impacts AF, offering a more effective approach than traditional medications. By tackling both obesity and AF simultaneously, the study aims to reduce the overall burden of cardiovascular disease, making it a compelling initiative for partners within the Dutch Cardiovascular Alliance (DCVA) and the Netherlands Heart Network (WCN).
The VERAPAF study focuses on the use of verapamil, a "forgotten" drug that offers advantages over starting treatment with beta-blockers for patients with paroxysmal atrial fibrillation (AF). Retrospective analyses suggest that patients on verapamil fare better than those using beta-blockers, requiring fewer cardioversions and fewer referrals for ablation. However, these benefits need to be proven through prospective research in order to change clinical guidelines.
